Tag Archives: Gilenya®

Novartis to acquire all remaining rights to Ofatumumab from GlaxoSmithKline plc (GSK)

Novartis strengthens multiple sclerosis focus with the addition of Ofatumumab to leading MS portfolio which includes Gilenya and investigational treatments BAF312 and CJM112 Ofatumumab is a fully human monoclonal antibody for relapsing remitting multiple sclerosis (RRMS) which targets CD20 and … Read the full press release

Novartis announces new Gilenya® analyses to be presented at the 67th American Academy of Neurology Annual Meeting in Washington, DC, April 18-25, 2015

New analysis will confirm high efficacy of Gilenya® in achieving ‘no evidence of disease activity’ (NEDA4) in previously-treated highly-active RMS patients Separate analyses will show adding brain shrinkage to an existing assessment tool enhances ability to predict disability progression in … Read the full press release